Drug intelligence / Profile preview

GLV-1h43

Development stage: Preclinical
Lead developer: Genelux
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intravenous, Intratumoral

Overview

GLV-1h43 is an engineered oncolytic vaccinia virus (VACV) derived from the Lister strain, developed by Genelux Corporation. It is a derivative of the GLV-1h68 (GL-ONC1) backbone, specifically modified to express the human sodium iodide symporter (hNIS) gene. This modification enables a theranostic approach to cancer treatment: the virus selectively replicates in and lyses tumor cells (oncolysis) while the expression of hNIS allows for non-invasive, real-time monitoring of viral distribution and replication using PET or SPECT imaging with radiotracers like I-124 or Tc-99m. Furthermore, the hNIS expression facilitates the targeted uptake of therapeutic radioisotopes, such as I-131, into infected tumor cells, thereby combining viral oncolysis with localized radiotherapy to enhance anti-tumor efficacy.

Other names: Vaccinia virus GLV-1h43hNIS-expressing vaccinia virus

Targets

NIS (Human sodium iodide symporter)

Beyond the preview

Go deeper on GLV-1h43.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLV-1h43.

Explore the full profile